title: Effects of citrate-enriched bicarbonate based dialysate on anticoagulation and dialyzer reuse in maintenance hemodialysis patients.
abstract: Systemic anticoagulation with unfractionated heparin is commonly used in maintenance hemodialysis (HD), but it increases the risk of bleeding complications. We investigated whether the use of citrate-enriched bicarbonate based dialysate (CD) would reduce systemic anticoagulation without compromising the efficacy of reprocessed dialyzers. This is a crossover study in which half of a total of 30 patients initially underwent HD with acetate-enriched bicarbonate based dialysate and a standard heparin dose of ∼ 100 IU/kg (Treatment A), whereas the remaining patients were treated with CD and a 30% reduced heparin dose (Treatment B). After 12 consecutive HD sessions in each treatment, the dialysate and heparin doses were reversed, then followed for another period of 12 HD sessions. The two treatment phases were split by a washout period of six HD sessions using acetate-enriched bicarbonate based dialysate and standard heparin dose. Systemic anticoagulation was higher in Treatment A. The activated partial thromboplastin time at the end of HD session was 68 ± 36 seconds in Treatment A and 47 ± 16 seconds in Treatment B (P = 0.005). Sixty-eight percent of the dialyzers remained adequate until the 12th use in Treatment A and 61% did so in Treatment B (P = 0.63). Patients had three and 24 cramps episodes during Treatment A and B, respectively (P < 0.001). Nine and 26 symptomatic intradialytic hypotension episodes were seen in Treatment A and B, respectively, (P = 0.003). In conclusion, the use of CD had a favorable effect on anticoagulation in the extracorporeal circuit in patients on maintenance HD, but it was also associated with more hypotension and cramps.
authors.affiliation: Hospital Universitário Antônio Pedro, Universidade Federal Fluminense, Niterói, Brazil.
authors.forename: Amanda D
authors.initials: AD
authors.lastname: Rocha
authors.forename: Vanessa C
authors.initials: VC
authors.lastname: Padua
authors.forename: Esther
authors.initials: E
authors.lastname: Oliveira
authors.forename: Márcia M
authors.initials: MM
authors.lastname: Guimaraes
authors.forename: Jocemir R
authors.initials: JR
authors.lastname: Lugon
authors.forename: Jorge P
authors.initials: JP
authors.lastname: Strogoff de Matos
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001639:Bicarbonates / Q000737:chemistry*; D001777:Blood Coagulation / Q000187:drug effects*; D019343:Citric Acid / Q000737:chemistry*; D018592:Cross-Over Studies; D015314:Dialysis Solutions / Q000737:chemistry*; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis / Q000009:adverse effects / Q000379:methods*; D055815:Young Adult
chemical_list: D001639:Bicarbonates; D015314:Dialysis Solutions; D019343:Citric Acid
keywords: Hemodialysis; anticoagulation; citric acid dialysate; heparin; reuse